DK1090645T3 - Oral tilförsel af kemisk modificerede proteiner - Google Patents

Oral tilförsel af kemisk modificerede proteiner

Info

Publication number
DK1090645T3
DK1090645T3 DK00122148T DK00122148T DK1090645T3 DK 1090645 T3 DK1090645 T3 DK 1090645T3 DK 00122148 T DK00122148 T DK 00122148T DK 00122148 T DK00122148 T DK 00122148T DK 1090645 T3 DK1090645 T3 DK 1090645T3
Authority
DK
Denmark
Prior art keywords
chemically modified
oral administration
modified proteins
csf
pegylated
Prior art date
Application number
DK00122148T
Other languages
English (en)
Inventor
Alan D Habberfield
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK1090645T3 publication Critical patent/DK1090645T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK00122148T 1994-02-08 1995-02-08 Oral tilförsel af kemisk modificerede proteiner DK1090645T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19418794A 1994-02-08 1994-02-08
US37912195A 1995-02-01 1995-02-01
EP95911690A EP0726778B1 (en) 1994-02-08 1995-02-08 Oral delivery system of chemically modified proteins g-csf

Publications (1)

Publication Number Publication Date
DK1090645T3 true DK1090645T3 (da) 2006-03-27

Family

ID=26889779

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00122148T DK1090645T3 (da) 1994-02-08 1995-02-08 Oral tilförsel af kemisk modificerede proteiner
DK95911690T DK0726778T3 (da) 1994-02-08 1995-02-08 Oral administration af kemisk modificerede proteiner

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK95911690T DK0726778T3 (da) 1994-02-08 1995-02-08 Oral administration af kemisk modificerede proteiner

Country Status (11)

Country Link
US (2) US20020099001A1 (da)
EP (2) EP0726778B1 (da)
AT (2) ATE203415T1 (da)
AU (1) AU1916295A (da)
DE (2) DE69521880T2 (da)
DK (2) DK1090645T3 (da)
ES (2) ES2251924T3 (da)
GR (1) GR3036625T3 (da)
IL (1) IL112583A0 (da)
PT (1) PT726778E (da)
WO (1) WO1995021629A1 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885567A (en) * 1993-10-22 1999-03-23 University Of Connecticut Treatment of infection in fowl by oral administration of avian interferon proteins
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
HU229888B1 (en) 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
BR9915548A (pt) 1998-10-16 2001-08-14 Biogen Inc Proteìnas de fusão de interferon-beta e usos
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
KR100773323B1 (ko) 2000-01-10 2007-11-05 맥시겐 홀딩스 리미티드 지-씨에스에프 접합체
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
EP1425304B9 (en) 2001-07-11 2010-09-08 Maxygen, Inc. G-csf conjugates
CN1774281B (zh) * 2003-04-15 2010-10-13 奥珀百思控股公司 包含蛋白质和/或多肽以及胶体颗粒的药物组合物
US7834147B2 (en) 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
US7943179B2 (en) * 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
AU2005306894B2 (en) 2004-11-05 2011-11-24 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
KR20080027291A (ko) 2005-06-01 2008-03-26 맥시겐 홀딩스 엘티디 피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법
KR100694994B1 (ko) 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
MX2010002448A (es) 2007-08-27 2010-10-04 Biogenerix Ag Formulacion liquida del g-csf conjugado.
WO2012018628A1 (en) 2010-07-26 2012-02-09 Board Of Regents, The University Of Texas System Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
US9974850B2 (en) 2013-01-25 2018-05-22 Board Of Regents, The University Of Texas System Immunogenic compositions and uses thereof
EP3534974B1 (en) * 2016-11-02 2024-08-21 Board of Regents, The University of Texas System Dissolvable films and methods of their use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2792862B2 (ja) * 1988-07-30 1998-09-03 寛治 高田 経口腸溶製剤
WO1990006952A1 (fr) * 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
DE69120141T2 (de) * 1990-03-28 1996-11-28 Shuji Kojima Polymerkombiniertes Arzneimittel zur Magenbehandlung und Verfahren zu dessen Herstellung
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US6565841B1 (en) * 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
FR2693907B1 (fr) * 1992-07-23 1994-09-02 Rhone Poulenc Rorer Sa Procédé d'administration de solutions de facteur de stimulation des colonies granulocytaires.
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods

Also Published As

Publication number Publication date
EP1090645A2 (en) 2001-04-11
EP0726778B1 (en) 2001-07-25
AU1916295A (en) 1995-08-29
DE69534676D1 (de) 2006-01-12
DE69534676T2 (de) 2006-08-17
ES2159630T3 (es) 2001-10-16
US20020099001A1 (en) 2002-07-25
ES2251924T3 (es) 2006-05-16
EP0726778A1 (en) 1996-08-21
DE69521880T2 (de) 2002-01-03
EP1090645A3 (en) 2002-02-27
DK0726778T3 (da) 2001-09-24
ATE203415T1 (de) 2001-08-15
US20030185795A1 (en) 2003-10-02
ATE311908T1 (de) 2005-12-15
GR3036625T3 (en) 2001-12-31
HK1036214A1 (en) 2001-12-28
PT726778E (pt) 2001-12-28
WO1995021629A1 (en) 1995-08-17
EP1090645B1 (en) 2005-12-07
IL112583A0 (en) 1995-05-26
DE69521880D1 (de) 2001-08-30

Similar Documents

Publication Publication Date Title
DK1090645T3 (da) Oral tilförsel af kemisk modificerede proteiner
DK0733067T3 (da) N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
NO20014415D0 (no) Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens
FR2762843B1 (fr) Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
DK0644932T3 (da) Oprensede former af DNase
CY1107391T1 (el) Αρυλσυμπυκνωμενες αζαπολυκυκλικες ενωσεις
FR2651677B1 (fr) Composition pharmaceutique a base de salmeterol et du propionate de fluticasone.
AU8296987A (en) Pharmaceutical composition comprising fluticasone propionate
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
NZ504771A (en) IFNAR2/ INFcomplex for prolonging the in vivo effects of type I interferon (INF)
HUP0202525A2 (hu) Mofetil mikofenolát és PEG-IFN-alfa együttes alkalmazása, valamint az azokat tartalmazó gyógyszerkészítmények és kit
ATE67783T1 (de) Homogene rekombinante immun-interferon-fragmente und diese enthaltende pharmazeutische zusammensetzungen.
OA07539A (fr) Nouveaux dérivés d'acides phényl aliphatiques, leur préparation, leur application comme médicaments, et les compositions les renfermant.
MA22343A1 (fr) Compositions type massepain, contenant du psyllium
OA07270A (fr) Dérivés N-(vinblastinoyl-23) d'acide aminés, leur préparation et leur application thérapeutique.
NZ215861A (en) Condensed triazole derivatives and pharmaceutical compositions
DE69706657D1 (de) Natürliches menschliches alpha interferon enthaltende pharmazeutische zusammensetzungen
ATE145333T1 (de) Hirudin enthaltende orale arzneimittel
NZ220539A (en) 1,4-dihydropyridine derivatives and pharmaceutical compositions
AU609435B2 (en) Prevention of bovine respiratory disease complex in cattle by administration of interferon
KR970701559A (ko) 펩타이드의 경구 투여를 위한 안정화된 조성물(stabilized composition for oral administration of peptides)
IT1251496B (it) Derivati imidazotiadiazolici ad attivita' diuretica, procedimenti per la loro preparazione e composizioni che li contengono
FR2722500B1 (fr) Derives d'acide 2-thienylimidazo(1,2-a) benzimidazole-3-acetique, leur preparation et leur application en therapeutique
IL81926A0 (en) Pharmaceutical compositions for the oral administration of active proteins
IT208775Z2 (it) Siringa per l'anestesia intraligamentosa.